featured
Anti–SARS-CoV-2 Antibody Responses Are Attenuated in Infliximab-Treated IBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Gut
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Anti–SARS-CoV-2 Antibody Responses Are Attenuated in Patients With IBD Treated With Infliximab
Gut 2021 May 01;70(5)865-875, NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, N Chanchlani, J Butterworth, R Cooney, NM Croft, AL Hart, PM Irving, KB Kok, CA Lamb, JK Limdi, J Macdonald, DP McGovern, SJ Mehta, CD Murray, KV Patel, RC Pollok, T Raine, RK Russell, CP Selinger, PJ Smith, J Bowden, TJ McDonald, CW Lees, S Sebastian, N Powell, T AhmadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.